Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation
TLDR
The bridging protocol in patients requiring surgery after recent PCI with DES seems adequate to prevent stent thrombosis in this high-risk group and the bleeding risk is not insignificant but in this patient group controllable without major late sequelae.Abstract:
Objectives
To evaluate stent-related adverse cardiac events and bleeding complications within 30 days after surgical procedures in patients with recent drug-eluting stent (DES) implantation, in whom a bridging protocol was used.read more
Citations
More filters
Journal ArticleDOI
Perioperative management of antiplatelet therapy
TL;DR: This review focuses on the pharmacological and pharmacokinetic properties of both older and novel antiplatelet drugs, and reviews current literature and guidelines addressing options for perioperativeAntiplatelet management.
Journal ArticleDOI
Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: A weighted meta-analysis of 280 patients from eight studies
Jeremy T. Warshauer,Vishal G. Patel,Georgios Christopoulos,Anna Kotsia,Subhash Banerjee,Emmanouil S. Brilakis +5 more
TL;DR: A weighted meta‐analysis of the outcomes in patients with coronary stents undergoing bridging with glycoprotein IIb/IIIa inhibitors prior to surgery is performed.
Journal ArticleDOI
The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention.
TL;DR: Noncardiac surgery may be required within the first year after percutaneous coronary intervention in approximately 4% of patients and is the second most common reason for premature discontinuation of antiplatelet therapy (APT), which may, in turn, increase the risk of perioperative ischemic events, particularly stent thrombosis.
Journal ArticleDOI
Perioperative management of antiplatelet therapy in patients undergoing non-cardiac surgery following coronary stent placement: a systematic review
Christopher P. Childers,Melinda Maggard-Gibbons,Melinda Maggard-Gibbons,Jesus G. Ulloa,Jesus G. Ulloa,Ian T. MacQueen,Ian T. MacQueen,Isomi M Miake-Lye,Roberta M. Shanman,Selene Mak,Selene Mak,Jessica M Beroes,Paul G. Shekelle +12 more
TL;DR: Evidence regarding perioperative APT management in patients with cardiac stents undergoing NCS is insufficient to guide practice and other clinical factors may have a greater impact on MACE and bleeding events.
Journal ArticleDOI
The aetiology of myocardial injury after non-cardiac surgery
TL;DR: Implementation of routine postoperative troponin assessment and accessible use of minimally invasive imaging should be considered to provide adequate individualised therapy and addition of preoperative imaging may improve the stratification of high-risk patients who may benefit from preoperative or perioperative interventions.
References
More filters
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
Jeffrey W. Moses,Martin B. Leon,Jeffrey J. Popma,Peter J. Fitzgerald,David R. Holmes,Charles O'Shaughnessy,Ronald P. Caputo,Dean J. Kereiakes,David O. Williams,Paul S. Teirstein,Judith Jaeger,Richard E. Kuntz +11 more
TL;DR: In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect, reducing the rates of restenosis and associated clinical events in all subgroups analyzed.
Journal ArticleDOI
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
Marie-Claude Morice,Patrick W. Serruys,J. Eduardo Sousa,Jean Fajadet,Ernesto Ban Hayashi,Marco Antonio Perin,Antonio Colombo,Gerhard Schuler,Paul Barragan,Giulio Guagliumi,Ferenc Molnar,Robert Falotico +11 more
TL;DR: As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.
Journal ArticleDOI
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
Ioannis Iakovou,Thomas Schmidt,Erminio Bonizzoni,Lei Ge,Giuseppe Sangiorgi,Goran Stankovic,Flavio Airoldi,Alaide Chieffo,Matteo Montorfano,Mauro Carlino,Iassen Michev,Nicola Corvaja,Carlo Briguori,Ulrich Gerckens,Eberhard Grube,Antonio Colombo +15 more
TL;DR: The cumulative incidence of stent thrombosis 9 months after successful drug-eluting stent implantation in consecutive "real-world" patients was substantially higher than the rate reported in clinical trials.
Journal ArticleDOI
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
Gregg W. Stone,Stephen G. Ellis,David A. Cox,James B. Hermiller,Charles O'Shaughnessy,James Tift Mann,Mark Turco,Ronald P. Caputo,Patrick Bergin,Joel Greenberg,Jeffrey J. Popma,Mary E. Russell +11 more
TL;DR: As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.